Skip to main content

Table 1 Population characteristics

From: Relationship between cardiovascular risk and lipid testing in one health care system: a retrospective cohort study

  Men Women
Total, N (row%) 24,540 (41.2) 35,064 (58.8)
  n (col%) n (col%)
Age
 25–34 2,306 (9.4) 3,697 (10.5)
 35–44 5,290 (21.6) 7,242 (20.7)
 45–54 7,133 (29.1) 9,946 (28.4)
 55–64 6,700 (27.3) 9,063 (25.9)
 65–79 3,111 (12.7) 5,116 (14.6)
Cardiovascular riska
 Low (<10 %) 7,661 (38.9) 24,192 (77.1)
 Moderate (10–20 %) 6,290 (31.9) 5,378 (17.1)
 High (>20 %) 5,745 (29.2) 1,798 (5.7)
 Missing 4,844 [19.7] 3,696 [10.5]
 Diabetes 552 (2.3) 710 (2.0)
 BP-lowering medications, any fill in past year 4,870 (19.9) 6,477 (18.5)
Systolic blood pressure
 ≤140 18,265 (84.7) 28,956 (88.6)
 141–160 2,817 (13.1) 3,103 (9.5)
 161–180 438 (2.0) 537 (1.6)
 >180 56 (0.3) 91 (0.3)
 Missing 2,964 [12.1] 2,377 [6.8]
Total cholesterol
 <200 6,745 (46.5) 8,781 (41.0)
 200–239 5,508 (38.0) 8,352 (39.0)
 ≥240 2,256 (15.6) 4,273 (20.0)
 Missing 10,031 [40.9] 13,658 [39.0]
HDL cholesterol
 <40 2,534 (17.5) 770 (3.6)
 40–59 8,135 (56.1) 7,569 (35.4)
 ≥60 3,838 (26.5) 13,060 (61.0)
 Missing 10,033 [40.9] 13,665 [39.0]
LDL cholesterol
 <100 2,207 (20.7) 3,721 (24.1)
 100–129 3,945 (37.1) 5,808 (37.6)
 130–159 3,094 (29.1) 4,049 (26.2)
 160–189 1,101 (10.3) 1,467 (9.5)
 ≥190 302 (2.8) 401 (2.6)
 Missing 13,891 [56.6] 19,618 [56.0]
BMI
 <25 4,761 (22.8) 12,481 (38.2)
 25–29.9 9,220 (44.1) 9.646 (29.5)
 ≥30 6,913 (33.1) 10,545 (32.3)
 Missing 3,646 [14.9] 2,392 [6.8]
 Current smoker 2,188 (13.5) 3,130 (9.1)
 Missing 843 [3.4] 587 [1.7]
RUB
 0 = No diagnoses 2,687 (11.0) 2,097 (6.0)
 1 = Low 3,519 (14.3) 4,158 (11.9)
 2 4,697 (19.1) 5,248 (15.0)
 3 11,929 (48.6) 19,557 (55.8)
 4 1,355 (5.5) 3,450 (9.8)
 5 = High 353 (1.4) 554 (1.6)
Health plan
 Medicare 3,309 (13.5) 5,382 (15.4)
 Medicaid/Basic Health 315 (1.3) 673 (1.9)
 Commercial 19,945 (81.3) 27,699 (79.0)
 Private pay 971 (4.0) 1,310 (3.7)
Annual average primary care visits, past 5 years
 <1 8,257 (33.7) 6,572 (18.7)
 1 to <2 9,326 (38.0) 12,055 (34.4)
 2 to <3 4,130 (16.8) 8,255 (23.5)
 ≥3 2,827 (11.5) 8,182 (23.3)
Residence
 Rural 660 (2.7) 914 (2.6)
 Urban 23,880 (97.3) 34,150 (97.4)
Race
 White 14,866 (84.0) 25,805 (82.8)
 Asian 1,418 (8.0) 3,105 (10.0)
 Black 916 (5.2) 1,301 (4.2)
 Mixed race/Other 490 (2.8) 951 (3.1)
 Missing 6,850 [27.9] 3,902 [11.1]
Neighborhood-level variables
Median household income
 <$40,000 5,371 (21.9) 7,643 (21.9)
 $40,000 to <$60,000 11,394 (46.5) 16,410 (46.9)
 $60,000 to <$80,000 5,606 (22.9) 8,014 (22.9)
 ≥$80,000 2,114 (8.6) 2,913 (8.3)
 Missing 55 [0.2] 84 [0.2]
Education, % with some college
 <50 % 2,687 (11.0) 3,953 (11.3)
 50 % to <60 % 4,096 (16.7) 5,968 (17.1)
 60 % to <70 % 6,407 (26.2) 9,215 (26.3)
 70 % to <80 % 5,973 (24.4) 8,554 (24.5)
 ≥80 % 5,319 (21.7) 7,289 (20.8)
 Missing 58 [0.2] 85 [0.2]
  1. aCVD Risk score based on BMI-based risk calculations. When BMI-risk was missing, we used lab-based risk calculations (n = 698). The CVD risk equations are as follows:
  2. BMI-based CVD Risk Equations:
  3. Male, not treated with antihypertensive medications
  4. 100*(1-(0.88431^(exp([3.11296*ln(AGE) + 0.79277*ln(BMI) + 1.85508*ln(SBP) + 0.70953*SMOKE + 0.53160*DIAB] -23.9388))))
  5. Male, treated with antihypertensive medications
  6. 100*(1-(0.88431^(exp([3.11296* ln(AGE) + 0.79277* ln(BMI) + 1.92672* ln(SBP) + 0.70953* SMOKE + 0.53160* DIAB] -23.9388))))
  7. Female, not treated with antihypertensive medications
  8. 100*(1-(0.94833^(exp([2.72107* ln(AGE) + 0.51125* ln(BMI) + 2.81291* ln(SBP) + 0.61868* SMOKE + 0.77763* DIAB] -26.0145))))
  9. Female, treated with antihypertensive medications
  10. 100*(1-(0.94833^(exp([2.72107* ln(AGE) + 0.51125* ln(BMI) + 2.88267* ln(SBP) + 0.61868* SMOKE + 0.77763* DIAB] -26.0145))))
  11. Lab-based CVD Risk Equations:
  12. Male, not treated with antihypertensive medications
  13. 100*(1-(0.88936^(exp([3.06117*ln(AGE) + 1.12370*ln(TC)+−0.93263*ln(HDL) + 0.65451*SMOKE + 0.57367*DIAB + 1.93303* ln(SBP)]-23.9802))))
  14. Male, treated with antihypertensive medications
  15. 100*(1-(0.88936^(exp([3.06117*ln(AGE) + 1.12370*ln(TC)+−0.93263*ln(HDL) + 0.65451*SMOKE + 0.57367*DIAB + 1.99881* ln(SBP)]-23.9802))))
  16. Female, not treated with antihypertensive medications
  17. 100*(1-(0.95012^(exp([2.32888*ln(AGE) + 1.20904*ln(TC)+−0.70833*ln(HDL) + 0.52873*SMOKE + 0.69154*DIAB + 2.76157* ln(SBP)] -26.1931))))
  18. Female, treated with antihypertensive medications
  19. 100*(1-(0.95012^(exp([2.32888*ln(AGE) + 1.20904*ln(TC)+−0.70833*ln(HDL) + 0.52873*SMOKE + 0.69154*DIAB + 2.82263* ln(SBP)] -26.1931))))
\